Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy
Successful umbilical cord blood hematopoietic stem cell transplantation in a patient with adult T-cell leukemia/lymphoma initially achieving complete remission with anti-CC chemokine receptor 4 antibody combined chemotherapy
复制标题
成人T细胞白血病/淋巴瘤患者成功脐带血造血干细胞移植，抗CC趋化因子受体4抗体联合化疗初步达到完全缓解
DOI：
10.11406/rinketsu.58.32
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Masuko M.
中科院分区：
文献类型：
--
作者：
Suwabe T;Shibasaki Y;Kaihatsu A;Katagiri T;Miyakoshi S;Fuse K;Kobayashi H;Ushiki T;Moriyama M;Takizawa J;Narita M;Sone H;Masuko M.
一名患有CHOP难治性成人T细胞白血病/淋巴瘤（ATLL）的62岁男性接受抗CC趋化因子受体4抗体（mogamulizumab）联合CHOP治疗，并获得完全缓解。在末次给予mogamulizumab后71天，他接受了使用降低强度预处理的脐带血移植（CBT）。在第16天确认脐带血植入。第60天诊断为II级急性移植物抗宿主病（GVHD），并通过给予甲基强的松龙控制。在CBT后9个月没有复发的证据。在所有这些时期，调节性T细胞在CD 4阳性T细胞中的比例都非常低。由于mogamulizumab减少了调节性T细胞，据报道，在同种异体干细胞移植前给予mogamulizumab的患者中，急性GVHD的频率和严重程度增加。对于异基因干细胞移植前使用mogamulizumab的患者，需要进一步的经验来选择最佳供体来源、移植期和GVHD预防。
A 62-year-old man with CHOP refractory adult T-cell leukemia/lymphoma (ATLL) received anti-CC chemokine receptor 4 antibody (mogamulizumab) combined with CHOP and achieved complete remission. At 71 days after the final administration of mogamulizumab, he received umbilical cord blood transplantation (CBT) using reduced intensity conditioning. Umbilical cord blood engraftment was confirmed on day16. Grade II acute graft-versus-host disease (GVHD) was diagnosed on day60 and was controlled by administration of methylprednisolone. There was no evidence of relapse at 9 months after CBT. Ratios of regulatory T cells in CD4 positive T cells were remarkably low during all of these periods. Since mogamulizumab reduces regulatory T cells, the frequency and severity of acute GVHD were reported to be increased in patients administered mogamulizumab before allogenic stem cell transplantation. Further experiences are needed for selecting optimal donor sources, the portability period and GVHD prophylaxis for patients using mogamulizumab before allogeneic stem cell transplantation.